Article Figures & Data
Figures
- Figure 1
- Breast cancer patients age at diagnosis trends over years (1998-2017) A) Saudi and B) none-Saudi.
- Figure 2
- Breast cancer AJCC stage trends over years (1998-2017) A) Saudi and B) none-Saudi.
- Figure 3
- Frequency of breast cancer molecular subtypes over years (1998-2017) in both groups.
Tables
Variables Nationality Saudis Non-Saudis Cancer type Ductal 261 (91.3) 185 (94.4) Lobular 20 (7.0) 9 (4.6) Other 5 (1.7) 2 (1.0) Cancer grade I 25 (8.7) 14 (7.1) II 156 (54.5) 111 (56.6) III 105 (36.7) 71 (36.2) Cancer stage I 26 (12.6) 21 (14.7) II 129 (62.3) 72(50.3) III 51 (24.6) 48 (33.6) IV 1 (0.5) 2 (1.4) - Table 2
- Prognostic and predictive biomarkers and molecular subtypes for breast cancer patients.
Biomarkers and molecular subtypes Saudi Non-Saudi ER status -ve 120 (42.7) 64 (45.7) +ve 161 (57.3) 76 (54.3) PR status -ve 154 (55.0) 79 (56.4) +ve 126 (45.0) 61 (43.6) Her2 status -ve 204 (74.7) 106 (77.4) +ve 69 (25.3) 31 (22.6) Ki67 Low 1-10% 61 (33.7) 27 (32.9) Intermediate 11-20% 21 (11.6) 6 (7.3) High >20% 99 (54.7) 49 (59.8) Molecular type Luminal-A 67 (23.4) 33 (23.6) Luminal-B 75 (26.2) 31 (22.1) Luminal-Her2 33 (11.5) 18 (12.9) Her2-enriched 38(13.3) 11 (7.9) Triple-negative 58 (20.3) 40 (28.6) Basal-like 15 (5.2) 7(5.0) -ve: negative, +ve: positive, ER: estrogen receptors, PR: progesterone receptor, Her2: human epidermal growth factor receptor-2
- Table 3
- Human epidermal growth factor receptor-2 positive breast cancer: comparison between Saudi and non-Saudi in relation to age at diagnosis.
Age at diagnosis Saudi Non-Saudi 21-30 7.2 3.2 31-40 24.6 9.7 41-50 21.7 35.5 51-60 33.3 35.5 61-70 10.1 6.5 71-80 1.4 9.7 >80 1.4 0.0
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.